ALK and adenocarcinoma: An updated analysis for patients treated from 2006 to 2014, which included EGFR and ALK status, showed improved survival up to 12 months overall with 15.2 months for adenocarcinoma and 9.2 months for non-adenocarcinoma patients [9].